Pirfenidone

Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].

Product Specifications

CAS Number

[53179-13-8]

Product Name Alternative

AMR69

UNSPSC

12352005

Hazard Statement

H302

Target

CCR; TGF-beta/Smad

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Pirfenidone.html

Purity

99.99

Solubility

DMSO : ≥ 100 mg/mL|H2O : 12.5 mg/mL (ultrasonic)

Smiles

O=C1C=CC(C)=CN1C2=CC=CC=C2

Molecular Formula

C12H11NO

Molecular Weight

185.23

Precautions

H302

References & Citations

[1]Burghardt I, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354 (2) :542-7.|[2]Nakazato H, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002 Jun 20;446 (1-3) :177-85.|[3]Yang Y, et al. Inhibition of Pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transitionof human lens epithelial cells line SRA01/04. PLoS One. 2013;8 (2) :e56837.|[4]Inomata M, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014 Feb 8;15:16.|[5]Brooks D, et al. Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 2018 May 4;9 (34) :23462-23481.